HRP20211756T1 - Novi senzibilizacijsko-pojačivački režimi koji uključuju imunogene polipeptide koje kodiraju polinukleotidi - Google Patents
Novi senzibilizacijsko-pojačivački režimi koji uključuju imunogene polipeptide koje kodiraju polinukleotidi Download PDFInfo
- Publication number
- HRP20211756T1 HRP20211756T1 HRP20211756TT HRP20211756T HRP20211756T1 HR P20211756 T1 HRP20211756 T1 HR P20211756T1 HR P20211756T T HRP20211756T T HR P20211756TT HR P20211756 T HRP20211756 T HR P20211756T HR P20211756 T1 HRP20211756 T1 HR P20211756T1
- Authority
- HR
- Croatia
- Prior art keywords
- rsv
- nucleic acid
- use according
- adenoviral vector
- intended
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 14
- 229920001184 polypeptide Polymers 0.000 title claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 11
- 230000002163 immunogen Effects 0.000 title claims 6
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
- 241000725643 Respiratory syncytial virus Species 0.000 claims 17
- 239000013598 vector Substances 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 150000007523 nucleic acids Chemical class 0.000 claims 9
- 229940001442 combination vaccine Drugs 0.000 claims 8
- 108020001507 fusion proteins Proteins 0.000 claims 7
- 102000037865 fusion proteins Human genes 0.000 claims 7
- 238000003776 cleavage reaction Methods 0.000 claims 5
- 230000007017 scission Effects 0.000 claims 5
- 108060003393 Granulin Proteins 0.000 claims 4
- 102000011931 Nucleoproteins Human genes 0.000 claims 4
- 108010061100 Nucleoproteins Proteins 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 206010070834 Sensitisation Diseases 0.000 claims 3
- 230000001235 sensitizing effect Effects 0.000 claims 3
- 241000282576 Pan paniscus Species 0.000 claims 2
- 241000282577 Pan troglodytes Species 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000008313 sensitization Effects 0.000 claims 2
- 238000002255 vaccination Methods 0.000 claims 2
- 102000005593 Endopeptidases Human genes 0.000 claims 1
- 108010059378 Endopeptidases Proteins 0.000 claims 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 241000709664 Picornaviridae Species 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000223104 Trypanosoma Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Claims (12)
1. Kombinirano cjepivo koje sadrži:
(a) senzibilizacijski pripravak koji sadrži adenovirusni vektor koji sadrži nukleinskokiselinski konstrukt koji kodira imunogene polipeptide i
(b) najmanje jedan pojačivački pripravak koji sadrži MVA vektor koji sadrži nukleinskokiselinski konstrukt koji kodira imunogene polipeptide
pri čemu nukleinskokiselinski konstrukti koje sadrže prvi i drugi vektor kodiraju iste polipeptide: (i) fuzijski protein F iz respiratornog sincicijskog virusa (RSV), (ii) nukleoprotein N iz RSV i (iii) matrični protein M2 iz RSV,
namijenjeno upotrebi u senzibilizacijsko-pojačivačkom režimu cijepljenja, pri čemu se senzibilizacijski pripravak primjenjuje intranazalno, a najmanje jedan pojačivački pripravak se uglavnom primjenjuje intramuskularno.
2. Kombinirano cjepivo u skladu s patentnim zahtjevom 1, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, pri čemu je adenovirusni vektor adenovirusni vektor dobiven iz neljudskog velikog čovjekolikog majmuna, po mogućnosti adenovirusni vektor iz čimpanze ili bonoba.
3. Kombinirano cjepivo u skladu s bilo kojim od prethodnih patentnih zahtjeva, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, pri čemu su najmanje dva polipeptida koje kodiraju prvi i drugi nukleinskokiselinski konstrukt spojeni mjestom cijepanja.
4. Kombinirano cjepivo u skladu s patentnim zahtjevom 3, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, pri čemu je mjesto cijepanja samocijepajuće mjesto ili mjesto cijepanja endopeptidazom.
5. Kombinirano cjepivo u skladu s patentnim zahtjevom 4, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, pri čemu je samocijepajuće mjesto mjesto cijepanja 2A kojeg se bira iz skupine koju čine virusni peptid 2A ili peptid sličan 2A iz roda Picornavirus, virusa kukaca, iz porodice Aphtoviridae, iz roda Rotavirus i parazita iz roda Trypanosoma, po mogućnosti pri čemu je mjesto cijepanja 2A peptid 2A iz virusa bolesti slinavke i šapa.
6. Kombinirano cjepivo koje sadrži:
a) senzibilizacijski pripravak koji sadrži adenovirusni vektor koji sadrži nukleinskokiselinski konstrukt koji kodira najmanje jedan imunogeni polipeptid kojeg se bira iz skupine koju čine (i) fuzijski protein F iz respiratornog sincicijskog virusa (RSV), (ii) nukleoprotein N iz RSV i (ii) matrični protein M2 iz RSV, i
b) najmanje jedan pojačivački pripravak koji sadrži najmanje jedan imunogeni polipeptid koji je fuzijski protein F iz RSV,
pri čemu nukleinskokiselinski konstrukt kodira najmanje fuzijski protein F iz RSV, namijenjen upotrebi u senzibilizacijsko-pojačivačkom režimu cijepljenja, pri čemu se senzibilizacijski pripravak primjenjuje intramuskularno ili intranazalno, a najmanje jedan pojačivački pripravak se uglavnom primjenjuje intramuskularno.
7. Kombinirano cjepivo namijenjeno upotrebi u skladu s patentnim zahtjevom 6, pri čemu je adenovirusni vektor adenovirusni vektor dobiven iz neljudskog velikog čovjekolikog majmuna, po mogućnosti adenovirusni vektor iz čimpanze ili bonoba.
8. Kombinirano cjepivo namijenjeno upotrebi u skladu s patentnim zahtjevom 6 ili patentnim zahtjevom 7, pri čemu nukleinskokiselinski konstrukt kodira najmanje dva polipeptida.
9. Kombinirano cjepivo namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 6 do 8, pri čemu nukleinskokiselinski konstrukt kodira polipeptidi koji sadrže (i) fuzijski protein F iz RSV, (ii) nukleoprotein N iz RSV i (iii) matrični protein M2 iz RSV.
10. Kombinirano cjepivo namijenjeno upotrebi u skladu s patentnim zahtjevom 9, pri čemu nukleinskokiselinski konstrukt kodira (i) fuzijski protein F iz RSV, (ii) nukleoprotein N iz RSV i (iii) matrični protein M2 iz RSV, no ne kodira nikakav dodatni polipeptid.
11. Kombinirano cjepivo namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 6 do 10, pri čemu pojačivački pripravak ne sadrži imunogene polipeptide osim fuzijskog proteina F iz RSV.
12. Kombinirano cjepivo namijenjeno upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu svaki od senzibilizacijskog pripravka i pojačivačkog pripravka sadrži najmanje jedan dodatni spoj kojeg se bira iz skupine koju čine farmaceutski prihvatljivi nosači, farmaceutska pomoćna sredstva i adjuvansi.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/063196 WO2014005643A1 (en) | 2012-07-05 | 2012-07-05 | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
| PCT/EP2013/064286 WO2014006191A1 (en) | 2012-07-05 | 2013-07-05 | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
| EP13734111.1A EP2869841B1 (en) | 2012-07-05 | 2013-07-05 | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211756T1 true HRP20211756T1 (hr) | 2022-02-18 |
Family
ID=52780606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211756TT HRP20211756T1 (hr) | 2012-07-05 | 2013-07-05 | Novi senzibilizacijsko-pojačivački režimi koji uključuju imunogene polipeptide koje kodiraju polinukleotidi |
Country Status (5)
| Country | Link |
|---|---|
| EP (2) | EP3842068A1 (hr) |
| CY (1) | CY1124712T1 (hr) |
| HR (1) | HRP20211756T1 (hr) |
| PL (1) | PL2869841T3 (hr) |
| SI (1) | SI2869841T1 (hr) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6180398B1 (en) | 1996-07-12 | 2001-01-30 | Virogeneitics Corporation | Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation |
| EP3269390B1 (en) | 2004-01-23 | 2021-02-17 | MSD Italia S.r.l. | Chimpanzee adenovirus vaccine carriers |
| WO2008085502A2 (en) * | 2007-01-05 | 2008-07-17 | Inseron, Inc. | A green fluorescent protein optimized for expression with self-cleaving polypeptides |
| WO2009025770A2 (en) * | 2007-08-17 | 2009-02-26 | Wyeth | A heterologous prime-boost immunization regimen |
| GB0823497D0 (en) * | 2008-12-24 | 2009-01-28 | Isis Innovation | Immunogenic composition and use thereof |
| JP5882741B2 (ja) | 2009-02-02 | 2016-03-09 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サルアデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用 |
| WO2012021730A2 (en) * | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
| WO2012085936A2 (en) * | 2010-12-20 | 2012-06-28 | Panacea Biotech Ltd | Recombinant respiratory syncytial virus plasmids and vaccines |
| WO2012089231A1 (en) | 2010-12-30 | 2012-07-05 | Okairòs Ag | Paramyxovirus vaccines |
| WO2013139916A1 (en) | 2012-03-22 | 2013-09-26 | Crucell Holland B.V. | Vaccine against rsv |
-
2013
- 2013-07-05 EP EP20213823.6A patent/EP3842068A1/en active Pending
- 2013-07-05 SI SI201331936T patent/SI2869841T1/sl unknown
- 2013-07-05 HR HRP20211756TT patent/HRP20211756T1/hr unknown
- 2013-07-05 EP EP13734111.1A patent/EP2869841B1/en active Active
- 2013-07-05 PL PL13734111T patent/PL2869841T3/pl unknown
-
2021
- 2021-11-10 CY CY20211100977T patent/CY1124712T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2869841T1 (sl) | 2022-02-28 |
| EP2869841B1 (en) | 2021-08-25 |
| EP3842068A1 (en) | 2021-06-30 |
| PL2869841T3 (pl) | 2022-01-24 |
| EP2869841A1 (en) | 2015-05-13 |
| CY1124712T1 (el) | 2022-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210750T1 (hr) | Ekspresijski sustavi | |
| HRP20171703T1 (hr) | Predfuzijski antigeni rsv f | |
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| JP2019501208A5 (hr) | ||
| EA201270062A1 (ru) | Вакцина | |
| HRP20171213T1 (hr) | Glikoproteinske čestice nalik virusu (vlp) bjesnoće | |
| ATE552846T1 (de) | Verbesserter grippeimpfstoff | |
| JP2016513638A5 (hr) | ||
| HRP20190791T1 (hr) | Režim imuniziranja protiv rsv | |
| JP2008530245A5 (hr) | ||
| HRP20150479T1 (hr) | Multimeriäśna multiepitopska cjepiva protiv influence | |
| CY1111553T1 (el) | Φαρμακοτεχνικες μορφες εμβολιου γριπης για ενδοδερμικη χορηγηση | |
| JP2009523422A5 (hr) | ||
| WO2014160463A8 (en) | Prefusion rsv f proteins and their use | |
| JP2014530010A5 (hr) | ||
| JP2015509707A5 (hr) | ||
| RU2017137357A (ru) | Быстрорастворяющаяся лекарственная форма пероральной вакцины, в которой используют крахмал | |
| BR112015010756A8 (pt) | vacina de emergência baseada em peptídeo sintético contra doença do pé-e-boca (fmd) | |
| CN104780937A (zh) | 涉及由多核苷酸编码的免疫原性多肽的新型初免-加强方案 | |
| WO2006115843A3 (en) | Nipah virus vaccines | |
| RU2020117081A (ru) | Жидкие стабильные вакцины, содержащие вирус крупного рогатого скота | |
| JP2010535026A5 (hr) | ||
| RU2015138530A (ru) | Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа | |
| JP2013518052A5 (hr) | ||
| JP2015533376A5 (hr) |